We are live on ! Find out more
IBIO icon

iBio
IBIO

20 hedge funds and large institutions have $731K invested in iBio in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

43% more capital invested

Capital invested by funds: $510K → $731K (+$221K)

33% more funds holding

Funds holding: 15 → 20 (+5)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
20
Holders Change
+5
Holders Change %
+33.33%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$36.7K
2
Citadel Advisors
Citadel Advisors
Florida
+$27.3K
3
UBS Group
UBS Group
Switzerland
+$17.8K
4
VF
Virtu Financial
New York
+$11.5K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$10.5K

Top Sellers

Rank Fund Capital Flow
1
ACP
Aveo Capital Partners
Colorado
-$13K
2
BlackRock
BlackRock
New York
-$3.15K

IBIO Hedge Fund Activity: Q1 2018 in Review

20 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q1 2018, worth a combined $731K — up 43% from $510K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new IBIO positions and 1 closed out — a net gain of 5 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, adding an estimated $36.7K. The largest seller was Aveo Capital Partners, exiting entirely with an estimated $13K sold.

  • 20 institutional investors held iBio (IBIO) as of Q1 2018, up from 15 in Q4 2017.
  • Funds reported $731K of iBio stock for Q1 2018, up 43% quarter-over-quarter.
  • 6 funds opened new iBio positions in Q1 2018 and 1 closed out, a net change of +5 holders.
  • The largest iBio buyer in Q1 2018 was Vanguard Group, an estimated $36.7K added.
  • The largest iBio seller in Q1 2018 was Aveo Capital Partners, an estimated $13K sold.

Based on aggregated 13F filings for Q1 2018.